Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Evenity

    - PMLiVE

    Amgen reports positive results from landmark cardiovascular study

    The study found significant reductions of major cardiovascular events in high-risk adults following treatment

    - PMLiVE

    UCB’s Fintepla shows positives results for Lennox-Gastaut syndrome

    The study demonstrated a sustained reduction in seizures for patients

    - PMLiVE

    ViiV Healthcare receives NICE recommendation for HIV prevention therapy

    The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales

    - PMLiVE

    Pfizer’s Lorviqua recommended by NICE for lung cancer

    Lung cancer is the leading cause of cancer-related deaths worldwide

    - PMLiVE

    Amgen commits $650m to US manufacturing expansion

    The investment is expected to generate up to 750 new jobs

    - PMLiVE

    Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis

    The phase 3 study included around 2,600 patients

    - PMLiVE

    NICE recommends ALK’s immunotherapy to target underlying cause of hay fever

    An estimated 26,800 people in England with moderate-to-severe cases could benefit from Itulazax

    - PMLiVE

    NICE recommends BeOne’s Brukinsa to treat mantle cell lymphoma on NHS

    Approximately 600 people are affected by the form of non-Hodgkin lymphoma every year in the UK

    - PMLiVE

    Novartis’ Kisqali recommended by NICE to treat broad early breast cancer population

    The drug was previously available only for patients whose cancer had spread to nearby lymph nodes

    - PMLiVE

    Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE

    The rare inherited disease affects approximately 11,000 people in the UK

    - PMLiVE

    Amgen’s bemarituzumab shows promise in phase 3 gastric cancer study

    Almost one million new cases of gastric cancer are diagnosed globally every year

    - PMLiVE

    UCB shares promising results for fenfluramine in ultra-rare form of epilepsy

    CDKL5 deficiency disorder occurs in approximately one in 40,000 to 60,000 live births

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links